Study · Randomized controlled trial · 2021

19 results

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K

The New England journal of medicine25 Jun 2021Cited by 1,535 (Europe PMC)

PMID34170647DOI10.1056/nejmoa2107519PepBankPUB-34170647

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study19

19 results from studies that gave the peptide. 19 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 5 mg lowered HbA1c by 2.01 percentage points, more than semaglutide 1 mg, at 40 weeks.
In plain wordsIn adults with type 2 diabetes, tirzepatide 5 mg lowered HbA1c more than semaglutide 1 mg after 40 weeks.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change, tirzepatide 5 mg
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mg once weekly · 40 weeksAs given in this study (human).
Measurements
HbA1c change
−2.01 percentage points
tirzepatide 5 mg
Estimated difference vs semaglutide
−0.15 percentage points
tirzepatide 5 mg
Source sentences
Summary
The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide
2 context sentences(design, population, supporting numbers)
Summary · context
-0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064701
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 mg lowered HbA1c by 2.24 percentage points, more than semaglutide 1 mg, at 40 weeks.
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 mg lowered HbA1c more than semaglutide 1 mg after 40 weeks.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change, tirzepatide 10 mg
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg once weekly · 40 weeksAs given in this study (human).
Measurements
HbA1c change
−2.24 percentage points
tirzepatide 10 mg
Estimated difference vs semaglutide
−0.39 percentage points
tirzepatide 10 mg
Source sentences
Summary
The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide
2 context sentences(design, population, supporting numbers)
Summary · context
-0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064702
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 15 mg lowered HbA1c by 2.30 percentage points, more than semaglutide 1 mg, at 40 weeks.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered HbA1c more than semaglutide 1 mg after 40 weeks.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change, tirzepatide 15 mg
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mg once weekly · 40 weeksAs given in this study (human).
Measurements
HbA1c change
−2.3 percentage points
tirzepatide 15 mg
Estimated difference vs semaglutide
−0.45 percentage points
tirzepatide 15 mg
Source sentences
Summary
The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide
2 context sentences(design, population, supporting numbers)
Summary · context
-0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064703
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, semaglutide 1 mg lowered HbA1c by 1.86 percentage points at 40 weeks.
In plain wordsIn adults with type 2 diabetes, semaglutide 1 mg lowered HbA1c after 40 weeks, by less than tirzepatide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change, semaglutide 1 mg
Study
n: not reported in source
Comparator
Tirzepatide 5, 10 or 15 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg once weekly · 40 weeksAs given in this study (human).
Measurements
HbA1c change
−1.86 percentage points
semaglutide 1 mg
Source sentences
Summary
The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064704
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 5 mg reduced body weight more than semaglutide 1 mg (difference -1.9 kg).
In plain wordsIn adults with type 2 diabetes, tirzepatide 5 mg reduced body weight more than semaglutide 1 mg.
Peptide
Tirzepatide
Outcome
DecreaseBody weight reduction, tirzepatide 5 mg vs semaglutide
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Estimated treatment difference body weight
−1.9 kg
tirzepatide 5 mg vs semaglutide
Source sentences
Summary
Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064705
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 mg reduced body weight more than semaglutide 1 mg (difference -3.6 kg).
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 mg reduced body weight more than semaglutide 1 mg.
Peptide
Tirzepatide
Outcome
DecreaseBody weight reduction, tirzepatide 10 mg vs semaglutide
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Estimated treatment difference body weight
−3.6 kg
tirzepatide 10 mg vs semaglutide
Source sentences
Summary
Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064706
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 15 mg reduced body weight more than semaglutide 1 mg (difference -5.5 kg).
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg reduced body weight more than semaglutide 1 mg.
Peptide
Tirzepatide
Outcome
DecreaseBody weight reduction, tirzepatide 15 mg vs semaglutide
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Estimated treatment difference body weight
−5.5 kg
tirzepatide 15 mg vs semaglutide
Source sentences
Summary
Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064707
08HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, nausea occurred in 17 to 22% of patients on tirzepatide and 18% on semaglutide; events were mostly mild to moderate.
In plain wordsIn adults with type 2 diabetes, nausea affected 17 to 22% of people on tirzepatide and 18% on semaglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedNausea
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5, 10 or 15 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Nausea
17 to 22%
tirzepatide
Nausea
18%
semaglutide
Source sentences
Summary
The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064708
09HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, diarrhea occurred in 13 to 16% of patients on tirzepatide and 12% on semaglutide; events were mostly mild to moderate.
In plain wordsIn adults with type 2 diabetes, diarrhea affected 13 to 16% of people on tirzepatide and 12% on semaglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedDiarrhea
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5, 10 or 15 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Diarrhea
13 to 16%
tirzepatide
Diarrhea
12%
semaglutide
Source sentences
Summary
The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064709
10HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, vomiting occurred in 6 to 10% of patients on tirzepatide and 8% on semaglutide; events were mostly mild to moderate.
In plain wordsIn adults with type 2 diabetes, vomiting affected 6 to 10% of people on tirzepatide and 8% on semaglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedVomiting
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5, 10 or 15 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Vomiting
6 to 10%
tirzepatide
Vomiting
8%
semaglutide
Source sentences
Summary
The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064710
11HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, nausea occurred in 18% of patients on semaglutide 1 mg; events were mostly mild to moderate.
In plain wordsIn adults with type 2 diabetes, nausea affected 18% of people on semaglutide 1 mg.
Peptide
Semaglutide
Outcome
Direction not reportedNausea
Study
n: not reported in source
Comparator
Tirzepatide 5, 10 or 15 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Nausea
18%
semaglutide
Source sentences
Summary
The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064711
12HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, diarrhea occurred in 12% of patients on semaglutide 1 mg; events were mostly mild to moderate.
In plain wordsIn adults with type 2 diabetes, diarrhea affected 12% of people on semaglutide 1 mg.
Peptide
Semaglutide
Outcome
Direction not reportedDiarrhea
Study
n: not reported in source
Comparator
Tirzepatide 5, 10 or 15 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Diarrhea
12%
semaglutide
Source sentences
Summary
The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064712
13HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, vomiting occurred in 8% of patients on semaglutide 1 mg; events were mostly mild to moderate.
In plain wordsIn adults with type 2 diabetes, vomiting affected 8% of people on semaglutide 1 mg.
Peptide
Semaglutide
Outcome
Direction not reportedVomiting
Study
n: not reported in source
Comparator
Tirzepatide 5, 10 or 15 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Vomiting
8%
semaglutide
Source sentences
Summary
The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064713
14HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, hypoglycemia (blood glucose below 54 mg per deciliter) was reported in 0.6% of patients on tirzepatide 5 mg and 0.4% on semaglutide.
In plain wordsIn adults with type 2 diabetes, low blood sugar (below 54 mg per deciliter) occurred in 0.6% on tirzepatide 5 mg and 0.4% on semaglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedHypoglycemia, tirzepatide 5 mg
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Adverse events · Metabolic and weight
Studied dose
5 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Hypoglycemia
0.6%
tirzepatide 5 mg
Hypoglycemia
0.4%
semaglutide
Source sentences
Summary
Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064714
15HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, hypoglycemia (blood glucose below 54 mg per deciliter) was reported in 0.2% of patients on tirzepatide 10 mg and 0.4% on semaglutide.
In plain wordsIn adults with type 2 diabetes, low blood sugar (below 54 mg per deciliter) occurred in 0.2% on tirzepatide 10 mg and 0.4% on semaglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedHypoglycemia, tirzepatide 10 mg
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Adverse events · Metabolic and weight
Studied dose
10 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Hypoglycemia
0.2%
tirzepatide 10 mg
Hypoglycemia
0.4%
semaglutide
Source sentences
Summary
Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064715
16HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, hypoglycemia (blood glucose below 54 mg per deciliter) was reported in 1.7% of patients on tirzepatide 15 mg and 0.4% on semaglutide.
In plain wordsIn adults with type 2 diabetes, low blood sugar (below 54 mg per deciliter) occurred in 1.7% on tirzepatide 15 mg and 0.4% on semaglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedHypoglycemia, tirzepatide 15 mg
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Adverse events · Metabolic and weight
Studied dose
15 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Hypoglycemia
1.7%
tirzepatide 15 mg
Hypoglycemia
0.4%
semaglutide
Source sentences
Summary
Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064716
17HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, hypoglycemia (blood glucose below 54 mg per deciliter) was reported in 0.4% of patients on semaglutide 1 mg.
In plain wordsIn adults with type 2 diabetes, low blood sugar (below 54 mg per deciliter) was reported in 0.4% of people on semaglutide 1 mg.
Peptide
Semaglutide
Outcome
Direction not reportedHypoglycemia
Study
n: not reported in source
Comparator
Tirzepatide 5, 10 or 15 mg
Outcome group
Adverse events · Metabolic and weight
Studied dose
1 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Hypoglycemia
0.4%
semaglutide
Source sentences
Summary
Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064717
18HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, serious adverse events were reported in 5 to 7% of patients on tirzepatide and 3% on semaglutide.
In plain wordsIn adults with type 2 diabetes, serious side effects were reported in 5 to 7% on tirzepatide and 3% on semaglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedSerious adverse events
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Adverse events · Whole body
Studied dose
5, 10 or 15 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Serious adverse events
5 to 7%
tirzepatide
Serious adverse events
3%
semaglutide
Source sentences
Summary
Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064718
19HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, serious adverse events were reported in 3% of patients on semaglutide 1 mg.
In plain wordsIn adults with type 2 diabetes, serious side effects were reported in 3% of people on semaglutide 1 mg.
Peptide
Semaglutide
Outcome
Direction not reportedSerious adverse events
Study
n: not reported in source
Comparator
Tirzepatide 5, 10 or 15 mg
Outcome group
Adverse events · Whole body
Studied dose
1 mg once weekly · 40 weeksAs given in this study (human).
Measurements
Serious adverse events
3%
semaglutide
Source sentences
Summary
Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg.
Report a problemFND-3417064719

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials5

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

5 trials · 3 ongoing · 1 not yet recruiting · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 2/3NCT07734792

Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial

yifang zhun = 726est. 20 Sept 2026 to est. 31 Jul 2028

Acute Ischemic Stroke (AIS)

Trial page ClinicalTrials.govUpdated 1 Oct 2026

RecruitingPhase 2/3NCT07284511

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

McGill University Health Centre/Research Institute of the McGill University Health Centren = 10519 May 2026 to est. Jan 2029

Type 1 Diabetes · Type 1 Diabetes Mellitus · T1D · T1DM · T1DM - Type 1 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 27 May 2026

RecruitingPhase 2NCT06811324

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

The University of Texas Health Science Center at San Antonion = 201 Apr 2026 to est. 1 Jun 2027

Obesity Prevention · Sarcopenia in Elderly · Cardiovascular Function · GLP - 1 · Weight Loss

Trial page ClinicalTrials.govUpdated 15 Apr 2026

RecruitingPhase 4NCT06606821

The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

Tina Vilsbølln = 1241 Oct 2024 to est. 1 Aug 2028

Coronary Artery Disease · Coronary Microvascular Dysfunction · Overweight or Obesity · Stable Angina Pectoris · Chronic Coronary Artery Disease · Atherosclerosis Cardiovascular Disease

Trial page ClinicalTrials.govUpdated 22 May 2025

CompletedPhase 3Results postedNCT03987919

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

Eli Lilly and Companyn = 1,87930 Jul 2019 to 15 Feb 2021

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 14 Feb 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.